Ebrahim S Delpassand, M.D.
Chairman and CEO
Ebrahim S. Delpassand is the founder and current Chief Executive Officer of RadioMedix. He completed his residency training in Nuclear Medicine, and Anatomical and Clinical Pathology at Baylor College of Medicine in 1991. He is Board certified in Nuclear Medicine and Fellow of the American College of Nuclear Medicine.
Dr. Delpassand is the former Deputy Chairman and chief of Clinical Nuclear Medicine at the University of Texas, MD Anderson Cancer Center, a position that he held for 12 years. During his tenure at MD Anderson he supervised and managed 65 technical members of the Department consist of physicians, nurses, technologists, scientists and administrators with a budget exceeding $10 million per year and annual gross revenue of $50 million. In April of 1992, Dr. Delpassand and his wife Mrs. Azar Delpassand founded Infinity Care, a home healthcare company, and Infinity Infusion Care provider of pharmacy and home infusion therapy. The company grew to a 135 technical staff with 4 branches in Texas and pharmacy licenses in 35 States. Infinity Infusion Care was then acquired by a public company, Curative Healthcare, in July of 2002. In October of 2003, Dr. Delpassand left MD Anderson and founded Excel Diagnostics and Nuclear oncology Center with two locations in Houston. This organization is one of the premier outpatient Diagnostic Radiology and Nuclear Medicine facilities in Houston. This business has grown to have 40 fulltime employees. In addition to providing the full spectrum of state of the art diagnostic medical imaging and therapeutic Nuclear Medicine, Excel Diagnostics is heavily involved in sponsored clinical research and investigational projects. Excel is the only center currently authorized by FDA to provide Peptide Receptor Radionuclide Therapy (PRRT) to patients with Neuroendocrine Cancers in the entire United States under an approved Investigational New Drug (IND) application. Dr. Delpassand is the principle investigator on treatment with high activity In-111 Octreotide therapy and Lu-177 Octreotate PRRT. He also successfully applied and received Orphan Drug Designation for high activity In-111 Octreotide therapy. In January of 2006, Dr. Delpassand Founded RadioMedix, a biotechnology company with focus on development and marketing of new targeted radioactive diagnostic and therapeutic agents in the field of Nuclear Oncology.
Dr. Delpassand has authored more than 30 peer reviewed manuscripts in the field of Nuclear Medicine and Pathology and lectured in National and International meetings on Therapeutic Nuclear Medicine, PET, and monoclonal antibody imaging.Dr. Delpassand has served as the member of the Board of Directors of the Oncology Council of the Society of the Nuclear Medicine, RITA Foundation ( Non-Profit organization promoting early cancer diagnosis and therapy) , and as the member of advisory boards of University of St. Thomas in Houston, Biogen-Idec, Molecular Insight Pharmaceuticals, Southwest Bank of Texas ( Currently known as Amegy Bank) and Sterling Bank.
Link: Full CV for Dr. Ebrahim S. Delpassand
Azar Delpassand, R.N., BSN.
Ms. Delpassand has 20 years of experience as a serial entrepreneur in the healthcare industry and has co-founded three additional healthcare start-ups, including Infinity Infusion Care and Infinity Care, Inc. (named in 1997 as one of the 100 fastest growing businesses in Houston). She served as the President and CEO in both Infinity Infusion Care and Infinity Care, Inc.
Izabela Tworowska, Ph.D., M.Sc. Pharm.
Chief Scientific Officer
Dr. Tworowska is a co-founder of RadioMedix. She is conducting a scientific research at cross section of bioorganic and bioconjugate chemistry with special focus on design of theranostics agents targeting cancer cells. Dr. Tworowska’s research interests include development of multivalent probes targeting the metabolic pathways and the hedgehog signaling pathway. She is interested in the synthesis of macrocyclic chelators for multimodal imaging and application of carbon nanotubes as nanocarriers for theranostics applications. Originally trained as a clinical pharmacist and organic chemist, Dr. Tworowska completed her doctoral training in the Polish Academy of Science and Frankfurt University. During this time, she developed new methods for the synthesis of fluoro-modified oligonucleotides. Her postdoctoral fellowship at Rice University allowed her to gain experience in 2D and 3D NMR of oligonucleotides, RNAs and their complexes with proteins. She also completed the ACS Kauffman Entrepreneurial Program (FastTrac TechVenture). Dr. Tworowska received International Sigma-Aldrich Award, International Union and Pure and Applied Chemistry Award (IUPAC), and recently was selected to serve as observer on the IUPAC General Assembly. She publishes in peer-reviewed journals, and serves as a member on the NIH panel reviews and journal’s editorial boards. She is also a Chairman of Government Affairs Committee and Women Chemists Committee at the American Chemical Society–GHS.
Link: Full CV for Dr.Izabela Tworowska